Needham & Company Maintains a 'Hold' on Geron Corporation (GERN); Awaiting Data from Novel Programs to Drive Valuation Thesis
Tweet
Share
E-mailGet Alerts GERN Hot Sheet
Price: $1.47 -4.55%
Rating Summary:
12 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Geron Corporation (NASDAQ: GERN).
Needham analyst says, "We are encouraged by the initial safety data of GRNOPC1 and the potential for acceleration of the Phase 1 trial. Yet we note the hESC program is still in early stage without efficacy data to date and faces a long development pathway. We believe the oncology program may become the primary value driver for GERN stock. We believe the imetelstat trials are well designed to provide definitive answers on the clinical utility and potential for registration studies. We believe that GRN1005 further strengthens the Company’s product pipeline. Informative data from each program will likely be available by YE12. We maintain our rating, as we awaiting further sentinel events over the next 6-12 months to potentially drive GERN stock valuation higher, given the current ~$300MM technology value."
For more ratings news on Geron Corporation click here and for the rating history of Geron Corporation click here.
Shares of Geron Corporation closed at $3.85 yesterday.
Needham analyst says, "We are encouraged by the initial safety data of GRNOPC1 and the potential for acceleration of the Phase 1 trial. Yet we note the hESC program is still in early stage without efficacy data to date and faces a long development pathway. We believe the oncology program may become the primary value driver for GERN stock. We believe the imetelstat trials are well designed to provide definitive answers on the clinical utility and potential for registration studies. We believe that GRN1005 further strengthens the Company’s product pipeline. Informative data from each program will likely be available by YE12. We maintain our rating, as we awaiting further sentinel events over the next 6-12 months to potentially drive GERN stock valuation higher, given the current ~$300MM technology value."
For more ratings news on Geron Corporation click here and for the rating history of Geron Corporation click here.
Shares of Geron Corporation closed at $3.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- York Space Systems (YSS) PT Lowered to $18 at Needham
- NANO Nuclear Announces Participation in Several Investor Conferences
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
